Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 41 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: in vitro-treated peripheral blood stem cell transplantation Clear all

Conditions: Lymphoma, Neutropenia
Interventions: epoetin alfa, filgrastim, recombinant flt3 ligand, recombinant interleukin-3, sargramostim, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 17 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: busulfan, cyclophosphamide, cyclosporine, methotrexate, in vitro-treated peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Leukemia
Interventions: filgrastim, busulfan, cyclophosphamide, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: Up to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma (Skin)
Interventions: MART-1:27-35 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Hematologic Malignancies, Inborn Errors of Metabolism Disorders, Immune Deficiencies
Interventions: CliniMACS CD34 Reagent System; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: Up to 65 Years
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma Multiforme
Interventions: MGMTP140K-encoding retroviral vector, O6-benzylguanine, temozolomide, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Other + 2 more
Lead sponsor: Stanton Gerson MD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases
Interventions: filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin, recombinant interleukin-3, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes; Biological
Lead sponsor: Jessie L. Alexander; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Palo Alto, California

Conditions: Cervical Cancer
Interventions: human papillomavirus 16 E7 peptide, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: melphalan, recombinant interferon alfa, aldesleukin, in vitro-treated peripheral blood stem cell transplantation; Drug · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lymphoma
Interventions: filgrastim, sargramostim, carmustine, cisplatin, cyclophosphamide, etoposide, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 1991
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer
Interventions: filgrastim, carboplatin, cyclophosphamide, paclitaxel, thiotepa, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 3
States / cities: Detroit, Michigan • Buffalo, New York • Cleveland, Ohio

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 56 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Genetic + 3 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 45 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Leukemia, Lymphoma
Interventions: monoclonal antibody CD19, monoclonal antibody CD20, in vitro-treated peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants

BG & TMZ Therapy of Glioblastoma Multiforme

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Vaccine Therapy in Treating Patients With Recurrent or Persistent Cervical Cancer

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia